Aligos Therapeutics Inc.
South San Francisco, CA
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 1 Corporate Dr 2Nd Floor, South San Francisco, CA 94080, USA
- Website
- aligos.com
- Founded
- 2018
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $1,516,140 |
| FY2024 | $1,300,776 |
| FY2023 | $8,469,477 |
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| To conduct clinical development of a compound for the treatment of covid-19. | National Institute of Allergy and Infectious Diseases (NIH) | $11,286,393 |
SBA capabilities narrative
Aligos Therapeutics, Inc. is a clinical-stage
biopharmaceutical company founded with the mission to
improve patient outcomes by developing best-in-class
therapies for the treatment of liver and viral diseases.
Aligos applies its science driven approach and deep R&D
expertise to advance its purpose-built pipeline of
therapeutics for diseases with high unmet medical need
such as chronic hepatitis B infection (CHB), metabolic
dysfunction-associated steatohepatitis (MASH), and
coronaviruses.
Quick answers
Is Aligos Therapeutics Inc. registered in SAM.gov?
Yes. Aligos Therapeutics Inc.'s SAM.gov registration is active through October 29, 2027.
What is Aligos Therapeutics Inc.'s CAGE code?
Aligos Therapeutics Inc.'s CAGE code is 96ED3, and its Unique Entity ID (UEI) is ED19ABDRLV29.
How much has Aligos Therapeutics Inc. received in federal contracts?
Federal contracts obligated $1,516,140 to Aligos Therapeutics Inc. in fiscal year 2025 and $11,286,393 in fiscal years 2023 through 2027.
What is Aligos Therapeutics Inc.'s most recent federal award?
Aligos Therapeutics Inc.'s most recent federal contract award is To conduct clinical development of a compound for the treatment of covid-19 (75N93023C00052), from National Institute of Allergy and Infectious Diseases (NIH), on September 22, 2023.
On GovTribe
See Aligos Therapeutics Inc.'s full federal record
- Federal contract awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors